KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Other Non-Current Liabilities: 2020-2024

Historic Other Non-Current Liabilities for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $1.5 million.

  • AbCellera Biologics' Other Non-Current Liabilities fell 68.79% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 68.79%. This contributed to the annual value of $1.5 million for FY2024, which is 75.13% down from last year.
  • As of FY2024, AbCellera Biologics' Other Non-Current Liabilities stood at $1.5 million, which was down 75.13% from $5.9 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Other Non-Current Liabilities registered a high of $35.9 million during FY2021, and its lowest value of $1.5 million during FY2024.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $5.9 million (2023), whereas its average is $7.8 million.
  • As far as peak fluctuations go, AbCellera Biologics' Other Non-Current Liabilities surged by 292.28% in 2021, and later plummeted by 75.13% in 2024.
  • Over the past 5 years, AbCellera Biologics' Other Non-Current Liabilities (Yearly) stood at $9.1 million in 2020, then surged by 292.28% to $35.9 million in 2021, then slumped by 55.26% to $16.1 million in 2022, then plummeted by 63.21% to $5.9 million in 2023, then slumped by 75.13% to $1.5 million in 2024.